Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Innoviva Inc (NQ: INVA )

19.05 -0.09 (-0.47%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Innoviva Inc

< Previous 1 2 Next >
Innoviva to Participate in the Citi 2024 Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
Innoviva to Participate in the UBS Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Innoviva to Participate in Upcoming Investor Conferences
From Innoviva, Inc.
Via Business Wire
Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Innoviva to Participate in the BofA Securities Health Care Conference
From Innoviva, Inc.
Via Business Wire
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
From Innoviva Specialty Therapeutics
Via Business Wire
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
From Innoviva Specialty Therapeutics
Via Business Wire
Innoviva to Participate in the Cantor Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults
From Innoviva, Inc.
Via Business Wire
Innoviva Appoints Stephen Basso as Chief Financial Officer
From Innoviva, Inc.
Via Business Wire
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use
From Innoviva, Inc.
Via Business Wire
Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases
From Innoviva, Inc.
Via Business Wire
Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Innoviva Announces Retirement of Board Chairman
From Innoviva, Inc.
Via Business Wire
Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee
From Innoviva, Inc.
Via Business Wire
Innoviva Stock Trading Halted Today
From Innoviva, Inc.
Via Business Wire
Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic
From Innoviva, Inc.
Via Business Wire
Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Four Undervalued Healthcare Stocks for 2023
These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc. 
Via MarketBeat
Exposures COVID-19
Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)
From Innoviva, Inc.
Via Business Wire
Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022
--- Presentations Reinforce Topline Safety and Efficacy Findings and Highlight Consistency between Clinical and Microbiological Endpoints 
From Entasis Therapeutics Holdings Inc.
Via GlobeNewswire
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022
Six abstracts selected for presentation, including three oral presentations 
From Entasis Therapeutics Holdings Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.